BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus

Dingxie Liu, Joanna Xing, Barry Trink, Mingzhao Xing

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus'. Together they form a unique fingerprint.

Medicine & Life Sciences